Date: October 15, 2013  Administrative Circular: 2013:17

ATTN: Medical Health Officers and Branch Offices
     Public Health Nursing Administrators and Assistant Administrators
     Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2 – Immunization Program
   Section VII- Biological Products: DTaP-IPV and Tdap-IPV

DTaP-IPV:

The following changes have been made to the page:

1. Page has been reformatted to reflect the new format for the Biological Product Section.
2. * Note* Information relating to INFANRIX™-IPV supplied by GlaxoSmithKline Inc. has
   been added. This product will not be used in the BC publicly funded program in the
   foreseeable future, but recurrent supply interruptions of QUADRACEL® and new
   contractual arrangements may result in its future use. Therefore information is being
   provided to support such a change.
3. **Booster doses:**
   1. Deleted: No booster doses recommended at this time.
   2. Added: None using these products.
4. **Contraindications:**
   1. Deleted: “Children age 7 years and older”. Instead, age indications approved by
      Health Canada have been added to ‘Indications’ section.
   2. Revised to read: History of Guillain-Barré syndrome (GBS) within 8 weeks of receipt
      of a tetanus toxoid without any other cause being identified.
5. **Product components:** Now listed specifically for each vaccine. Please note that latex
   may be present in the rubber plunger stopper of INFANRIX™-IPV.
6. **Footnote:** Deleted footnote 2 about minimum intervals between doses; this information is
   contained in Section II of the manual.

Please remove and recycle page number: 3
Dated: June 2009

Please replace with new page number: 3
Dated: October 2013
**Tdap-IPV:**

The following changes have been made to the page:

1. Page has been reformatted to reflect the new format for the Biological Product Section.
2. **Indications:**
   1. Added: School entry booster (4-6 years of age), if DTaP-IPV is unavailable*.
   2. References to special populations (e.g., SOT) removed and replaced with wording: “Select special populations as indicated in Section III-Immunization of Special Populations.”

   *Note: When the higher potency product (DTaP-IPV) is available this product should be used. At this time we are forecasting a stock-out at BCCDC in late October of Quadracel® because of a delay in the expected lots of this product from Sanofi Pasteur. Options for alternate products were considered by the BC Immunization Committee and Adacel®Polio will be used until Quadracel® supply is re-established, likely late in 2013. Thereafter, Tdap-IPV will be maintained in small quantity based on health unit staff requests to enable offering of a combined vaccine instead of two separate injections to the small number of unimmunized or incompletely immunized people ≥ 7 years of age needing protection against tetanus, diphtheria, whooping cough and polio.

3. **Doses and schedule:**
   1. Added: 4-6 years of age: 1 dose given as 0.5 mL IM.
   2. Added/changed the following footnotes:
      a. Prior footnote A has been removed. Reference to Section II for immunization schedules for unimmunized older children and adults has been added to new footnote A.
      b. New footnote A: There is no minimum interval between a dose of Td and Tdap-IPV when Tdap-IPV is being given for pertussis and polio protection.
      c. Prior footnote B relating to adult SOT candidates or recipients has been removed, as this information is contained in the indications section.
      d. New footnote B states: Not necessary if the 4th dose of DTaP or Tdap-containing vaccine was given after the 4th birthday.

4. **Booster doses:**
   1. Deleted: No booster doses recommended at this time.
   2. Added: None using these products.

5. **Contraindications:**
   1. Revised to read history of Guillain-Barré syndrome (GBS) within 8 weeks of receipt of a tetanus toxoid without any other cause being identified.

6. **Special considerations:**
   1. Added: A hypotonic-hyporesponse episode (HHE) following a prior dose of pertussis-containing vaccine is not a contraindication to future immunization. This is added because of the addition of the school entry age group to the indications for use of this vaccine, should such a child have experienced HHE following a dose in infancy.
7. **Adverse events:**
   1. Removed: A nodule may be palpable at the injection site and may persist for several weeks. This is consistent with other Td containing pages.
   2. Removed: The interval between the childhood DTaP vaccine and a dose of Tdap-IPV does not affect the rate of injection site or systemic adverse events. This is true, but this concept is incorporated, without being explicitly stated, in the recommendation contained in Footnote A.

Please remove and recycle page number: 3a
Dated: May 2013

Please replace with new page numbers: 3a and 3b
Dated: October 2013

Please also remove both pages of the Table of Contents for Section VII – Biologicals Products dated September 2013 and replace with the enclosed updated pages of the Table of Contents section dated October 2013.

If you have any questions or concerns, please contact Brittany Deeter, Public Health Resource Nurse at telephone (604) 707-2577, fax (604) 707-2515 or by email at brittany.deeter@bccdc.ca

Sincerely,

Monika Naus, MD MHSc FRCPC FACP
Medical Director
Immunization Programs and Vaccine Preventable Diseases Service
BC Centre for Disease Control

pc: BC Ministry of Health:

Dr. Perry Kendall
Provincial Health Officer

Dr. Eric Young
Deputy Provincial Health Officer

Craig Thompson
Director, CD Prevention – Immunization

Warren O'Briain
Executive Director
Communicable Disease and Addiction Prevention